Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
REHOVOT, Israel and NEW YORK, March 07, 2018 -- AIT Therapeutics Inc. (OTC:AITB), a clinical-stage biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with serious lung infections and pulmonary hypertension, today announced that Steve Lisi, Chief Executive Officer, will provide a corporate overview at the 30th Annual ROTH Conference, and the 28th Annual Oppenheimer Healthcare Conference.
| 30th Annual ROTH Conference | ||
| Date: | Monday, March 12 | |
| Time: | 8:30am Pacific Time/11:30am Eastern Time | |
| Location: | Ritz Carlton, Laguna Niguel, California - BLUE Track - Salon 2 | |
| Webcast: | http://wsw.com/webcast/roth32/aitb/ | |
| Oppenheimer 28th Annual Healthcare Conference | ||
| Date: | Tuesday, March 20 | |
| Time: | 4:30pm Eastern Time | |
| Location: | Westin Grand Central Hotel, Track 3 | |
About AIT Therapeutics Inc.
AIT Therapeutics Inc. is a clinical-stage biopharmaceutical company using nitric oxide (NO) to treat serious lung infections and pulmonary hypertension. The Company is currently applying its therapeutic expertise to treat lower respiratory tract infections that are not effectively addressed with current standards of care. AIT Therapeutics is advancing its revolutionary NO respiratory targeted system in clinical trials for the treatment of bronchiolitis and nontuberculous mycobacteria (NTM). For more information, visit www.AIT-Pharm.com.
CONTACT
Steven Lisi
Chief Executive Officer
AIT Therapeutics, Inc.
[email protected]
Bob Yedid
LifeSci Advisors, LLC
[email protected]
(646) 597 6989
